Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: NTTG who wrote (12227)	7/15/2013 10:23:50 AM
From: mplaut	Read Replies (1) \| Respond to of 13111

According to Dr Robert Andtbacka in his "Current Status of Injectable Therapy" (available at video.healio.com at around 22:45) the comparative figures are: Injected lesions Non-injected lesions Non-injected systemic lesions IL2 70-97% 0 0 BCG 45-91 11-17 0 Allovectin 7 19 19 21 T-Vec 26 23 18 PV-10 49 37 33 ---------------------------------------------------------------- It seems that PV-10 has clear value.